×
Sunday, May 9, 2021

World Hypertension League Stresses upon the Implementation of "Call to Action for Global Hypertension Control"

Last updated Thursday, April 29, 2021 09:00 ET , Source: The European Society of Hypertension

ESH-ISH HYPERTENSION 2021 held virtually this year as a joint conference by the European Society of Hypertension & International Society of Hypertension

Rome, Italy, 04/29/2021 / SubmitMyPR /

The European Society of Hypertension-International Society of Hypertension hosted a Joint Conference virtually this year amid the Global Pandemic of COVID-19. The title of this virtual joint international conference was 'ESH-ISH HYPERTENSION 2021', and it was held from April 11-14, 2021, with live broadcast worldwide. Over 5,000 professionals in hypertension and related fields from around the world participated in this conference, and it focused primarily on implementing the Call to Action for Global Hypertension Control.

The President of the World Hypertension League, Professor Xin-Hua Zhang, delivered a keynote address on "Announcing and Promoting of the Call to Action for Global Hypertension Control". The World Hypertension League along with its global partners and member organizations drafted this speech.

According to the World Hypertension Congress that was held in São Paulo, Brazil, in 2019, despite being controllable, hypertension is not yet being properly controlled, leading risk factor for death and disability worldwide. There are more than 1.4 billion hypertensive patients around the world, but only less than 14% have their blood pressure under control.

The ESH-ISH HYPERTENSION 2021 called on global health authorities and medical professional societies to implement the following practices:

  1. Apply global best practices
  2. Help primary care services become central for hypertension prevention and control
  3. Promote teamwork among medical and non-medical staff to create patient-centered care.
  4. Use evidence-based standardized treatment protocol, and continuous supply of antihypertensive medicines that are of good quality, inexpensive, and long-lasting.
  5. Patients should be identified by regular outpatient clinics and population screening services, and blood pressure should be controlled promptly.
  6. Excellent leaders, services, and groups committed to hypertension prevention and control efforts should be recognized.

Professor Xin-Hua Zhang reported on the HEARTS Hypertension Control Project in China's Henan Province. The effect of introducing the "Call to Action on Global Hypertension Control" has been well shown. The initiative is being led by the government's health officials, with the help of an advisory group, and is being conducted by healthcare providers in about 1000 township hospitals and community health centers. The project employs globally validated blood pressure, glucose, uric acid, and lipid measuring instruments, as well as web-based clinical support and a quality monitoring system. The system connects the measurements to the prescription platform, provides information to support clinicians' decision-making on diagnosis, treatment, and planning for follow-up. It also offers regular and weekly assessments to advise regional government offices about the effectiveness and advancement of hypertension management in the regions, allowing health officials to provide timely assistance and oversight to primary health care providers. The HEARTS hypertension control initiative was introduced in July 2018, and as of December 31, 2020, the number of primary care providers involved in the project has grown from 54 to over 800, with more than 40,000 registered hypertensive patients having their blood pressure under control.

The World Health Organization and international medical specialist societies created the HEARTS technical kit, which provides strategic and practical advice. Its goal is to enhance primary care services' ability to monitor and avoid cardiovascular diseases. Government health authorities, professional teams, and healthcare providers are also advised to use the kit. It provides information on safe habits and patient self-management, an evidence-based regulated treatment framework, high-quality, continuous delivery of medications and critical medical equipment in the chosen algorithm, risk-based management plans, coordination and mutual responsibility, and a real-time quality tracking process. The HEARTS professional kit is recommended as a standard procedure in the "Call to Action for Hypertension Control."

Traditional Chinese medications with RCT proof of successfully lowering blood pressure should play a significant role in hypertension management in medical care. In primary care settings, using an evidence-based standardized treatment algorithm is the most effective way to improve hypertension control. Evidence-based, long-acting, high-quality, inexpensive, accessible, and effective medications must be used in the algorithm. Scientific data should also be used to endorse the dosage for each phase and the evaluation pace in the algorithm. Chinese patent conventional medications that follow the above guidelines can be chosen in addition to internationally recommended antihypertensive drugs. "Songling Xuemaikang," for example, has RCT proof of successfully lowering blood pressure and improving the lipid profile. It is appropriate for the majority of patients who are at high risk of cardiovascular disease.

"The results of the HEARTS hypertension control project in Henan, China, demonstrate that the 'Call to Action' and its recommended best practices are implementable, replicable, and sustainable," Professor Zhang concluded. "Widely dissemination of Call to Action can help improve the global hypertension control and help more hypertensive patients live longer and healthier."

The European Society of Hypertension - +39 06 330 531

Original Source of the original story >> World Hypertension League Stresses upon the Implementation of "Call to Action for Global Hypertension Control"


Updated: April 20th, 2021

KISS PR PRODUCT REVIEWER Compensation Disclosure & DISCLAIMER

Pursuant to the Federal Trade Commission's guidance of the public in conducting its affairs in conformity with legal requirements comprised in 16 C.F.R. § 255 et seq. on the use of endorsements and testimonials in advertising, this Product Reviewer Compensation Disclosure is provided by KissPR.com LLC and its affiliated entities (hereinafter referred to collectively as “KISS PR”). This disclosure applies to content displayed on all mobile, desktop, and other online versions of KISS PR’s websites and to those of KISS PR’s distribution partners (hereinafter referred to collectively as “the Websites”) and is provided for the purpose of disclosing the nature of the connection between KISS PR and product reviewers, advertisers, sponsors, endorsers, and other third-parties whose advertisements, sponsorships, endorsements, testimonials, opinions, or other product-related or service-related statements or reviews may appear on the Websites (hereinafter referred to as an "Product Reviewer").

This Product Reviewer Compensation Disclosure is intended to disclose to you that in consideration of payment of monetary and other compensation from a Product Reviewer, as described below, KISS PR sells various advertising, sponsorships, and marketing campaigns that are featured on one or more of the Websites.

There is a financial connection related to some of the products or services mentioned, reviewed, or recommended on the Websites between KISS PR and the Product Reviewer that owns, markets, or sells such product or service. If you decide to purchase a product or service featured on one or more of the Websites, KISS PR will not receive compensation related to that purchase from a Product Reviewer but may receive a one-time fee from the Product Reviewer for posting or distributing the product review on or via the Websites.

Further, KISS PR may post or otherwise promote on the Websites content (“Content”), including editorial content, which may feature third-party products and services (a "Reviewed Product"). This content may contain weblinks to third-party owned or operated web sites where you can purchase Reviewed Product (“Product Link”). If you click on a Product Link and then purchase a Reviewed Product on the linked web site, KISS PR will not receive compensation from the third-party offering the Reviewed Product (the “Vendor”).

Weblinks on the Websites featuring a Reviewed Product may be added to posts or articles that are not identified on the Websites as comprising or containing paid or sponsored content. In such case, a disclosure statement about the Reviewed Product and the compensation that KISS PR might receive in connection with its purchase by you will be included in such posts or articles. Further, third-party advertisements may be posted on the Websites. Each time you click on such an advertisement, KISS PR may receive compensation from the third-party advertiser, even if you do not purchase any product or service from that third-party.

KISS PR will, subject to the disclaimer of liability set forth below, endeavor to ensure that product or service endorsements appearing in the Websites or in posts or articles distributed via the Websites reflect the honest opinions, findings, beliefs, or experiences of the Product Reviewer as they relate to such product or service. However, Kiss PR exercises no editorial control over any of the Content and is not responsible for the editorial merit of any Content. If you have any complaint, concern, or question relating to the Content, including alleged infringement of any intellectual property rights, you should address your complaint, concern, or question directly to the Product Reviewer or the Vendor.

NO REPRESENTATIONS OR WARRANTIES; NON-RELIANCE. EXCEPT FOR ANY EXPRESS REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS DISCLOSURE STATEMENT, NEITHER KISS PR NOR ANY OTHER PERSON ON KISS PR’S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, EITHER ORAL OR WRITTEN, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE, TRADE, OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND YOU ACKNOWLEDGE THAT YOU HAVE NOT RELIED UPON ANY REPRESENTATION OR WARRANTY MADE BY KISS PR OR ANY OTHER PERSON ON KISS PR’S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN THIS DISCLOSURE STATEMENT.

DISCLAIMER of Liability. IN NO EVENT SHALL KISS PR BE LIABLE OR RESPONSIBLE TO YOU OR ANY OTHER PERSON FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR LOST OPPORTUNITIES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE AND REGARDLESS OF THE CAUSE OF ACTION UPON WHICH ANY SUCH CLAIM IS BASED, INCLUDING, WITHOUT LIMITATION, ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH ANY OF THE CONTENT, INCLUDING, WITHOUT LIMITATION, AUDIO, PHOTOGRAPHS, AND VIDEOS, OR OF THE ACCURACY, RELIABILITY, OR LEGALITY OF ANY STATEMENT MADE IN OR OMITTED FROM ANY advertisement, sponsorship, endorsement, testimonial, opinion, or other product-related or service-related statement or review appearing in the Websites or in ANY post or article distributed via the Websites.

© 2021 KissPR.com LLC



Media Contact Website: [KISS PR Brand Story PressWire] - Email: [email protected]